Renaissance Technologies LLC trimmed its position in shares of AbbVie Inc (NYSE:ABBV) by 48.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,220,056 shares of the company’s stock after selling 1,142,227 shares during the period. Renaissance Technologies LLC owned approximately 0.08% of AbbVie worth $115,393,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Signature Estate & Investment Advisors LLC acquired a new position in AbbVie during the 3rd quarter worth $112,000. Kiley Juergens Wealth Management LLC lifted its holdings in AbbVie by 69.3% during the 3rd quarter. Kiley Juergens Wealth Management LLC now owns 1,761 shares of the company’s stock worth $166,000 after buying an additional 721 shares in the last quarter. SRS Capital Advisors Inc. acquired a new position in AbbVie during the 3rd quarter worth $187,000. Biegel & Waller LLC acquired a new position in AbbVie during the 3rd quarter worth $206,000. Finally, Clearwater Capital Advisors LLC acquired a new position in AbbVie during the 3rd quarter worth $211,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.
Several research firms have issued reports on ABBV. Credit Suisse Group set a $85.00 price objective on AbbVie and gave the stock a “hold” rating in a report on Sunday, October 14th. Barclays reaffirmed a “hold” rating and set a $90.00 price objective on shares of AbbVie in a report on Sunday, November 4th. Bank of America reduced their price objective on AbbVie from $107.00 to $106.00 and set a “buy” rating on the stock in a report on Thursday, October 4th. Zacks Investment Research raised AbbVie from a “hold” rating to a “buy” rating and set a $105.00 price objective on the stock in a report on Monday, October 1st. Finally, Argus reduced their price objective on AbbVie from $130.00 to $115.00 and set a “buy” rating on the stock in a report on Tuesday, November 6th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $102.10.
In related news, Chairman Richard A. Gonzalez sold 16,850 shares of the firm’s stock in a transaction on Tuesday, December 11th. The stock was sold at an average price of $88.75, for a total transaction of $1,495,437.50. Following the sale, the chairman now owns 286,203 shares of the company’s stock, valued at approximately $25,400,516.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP William J. Chase sold 60,000 shares of the firm’s stock in a transaction on Wednesday, December 12th. The stock was sold at an average price of $90.00, for a total value of $5,400,000.00. Following the sale, the executive vice president now directly owns 104,863 shares in the company, valued at approximately $9,437,670. The disclosure for this sale can be found here. Insiders have sold a total of 263,440 shares of company stock worth $24,029,804 in the last ninety days. 0.07% of the stock is currently owned by company insiders.
ABBV stock opened at $88.31 on Monday. The firm has a market capitalization of $132.09 billion, a PE ratio of 15.77, a P/E/G ratio of 0.73 and a beta of 1.46. AbbVie Inc has a twelve month low of $77.50 and a twelve month high of $125.86.
AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, November 2nd. The company reported $2.14 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.01 by $0.13. The company had revenue of $8.24 billion for the quarter, compared to the consensus estimate of $8.23 billion. AbbVie had a return on equity of 2,006.63% and a net margin of 23.50%. The firm’s quarterly revenue was up 17.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.41 EPS. Sell-side analysts forecast that AbbVie Inc will post 7.94 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 15th. Investors of record on Tuesday, January 15th will be paid a dividend of $1.07 per share. This represents a $4.28 annualized dividend and a yield of 4.85%. The ex-dividend date is Monday, January 14th. This is an increase from AbbVie’s previous quarterly dividend of $0.96. AbbVie’s dividend payout ratio (DPR) is presently 68.57%.
AbbVie announced that its Board of Directors has approved a stock buyback program on Thursday, December 13th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 3.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.
ILLEGAL ACTIVITY WARNING: “Renaissance Technologies LLC Lowers Position in AbbVie Inc (ABBV)” was first reported by Fairfield Current and is owned by of Fairfield Current. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.fairfieldcurrent.com/news/2019/01/14/renaissance-technologies-llc-lowers-position-in-abbvie-inc-abbv.html.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.